Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back

被引:3
作者
Rossi, Valentina [1 ]
Turati, Alessandra [1 ]
Rosato, Antonio [1 ,2 ]
Carpanese, Debora [1 ]
机构
[1] Veneto Inst Oncol IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy
[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
关键词
triple negative breast cancer (TNBC); sacituzumab govitecan (IMMU-132); antibody-drug conjugate (ADC); Trop-2; immunotherapy; target therapeutics; metastatic TNBC; ANTIBODY-DRUG CONJUGATE; PROSTATE-CANCER; TROP2; RESISTANCE; MECHANISMS; BIOMARKER; EFFICACY; ANTIGEN;
D O I
10.3389/fimmu.2024.1447280
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Triple-negative breast cancer (TNBC) represents a major therapeutic challenge due to its heterogeneous and aggressive phenotype, and limited target-specific treatment options. The trophoblast cell surface antigen (Trop-2), a transmembrane glycoprotein overexpressed in various cancers, has emerged as a promising target for TNBC. Sacituzumab govitecan (SG), an antibody-drug conjugate (ADC) that targets Trop-2, has recently entered treatment algorithms for advanced and metastatic TNBC, independently from Trop-2 expression status, with manageable toxicity. Despite the impressive results, questions remain unsolved regarding its efficacy, safety profile, and Trop-2 biological role in cancer. Currently, Trop-2 cannot be designated as a predictive biomarker in SG treatment, albeit its expression correlates with disease outcome, yet its levels are not uniform across all TNBCs. Additionally, data regarding Trop-2 expression variations in primary and metastatic sites, and its interplay with other biomarkers are still ambiguous but mandatory in light of future applications of SG in other indications and settings. This poses the questions of a careful evaluation of the efficacy and toxicity profile of SG in such early stages of disease, and in personalized and combinatorial strategies. Research and clinical data are mandatory to address SG drawbacks and minimize its benefits, to realize its full potential as therapeutic agent in different epithelial tumors.
引用
收藏
页数:10
相关论文
共 90 条
[71]  
Shvartsur Anna, 2015, Genes Cancer, V6, P84
[72]  
Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
[73]   Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial [J].
Spring, L. M. ;
Tolaney, S. M. ;
Fell, G. ;
Bossuyt, V. ;
Abelman, R. O. ;
Wu, B. ;
Maheswaran, S. ;
Trippa, L. ;
Comander, A. ;
Mulvey, T. ;
McLaughlin, S. ;
Ryan, P. ;
Ryan, L. ;
Abraham, E. ;
Rosenstock, A. ;
Garrido-Castro, A. C. ;
Lynce, F. ;
Moy, B. ;
Isakoff, S. J. ;
Tung, N. ;
Mittendorf, E. A. ;
Ellisen, L. W. ;
Bardia, A. .
ANNALS OF ONCOLOGY, 2024, 35 (03) :293-301
[74]   Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? [J].
Staudacher, Alexander H. ;
Brown, Michael P. .
BRITISH JOURNAL OF CANCER, 2017, 117 (12) :1736-1742
[75]   Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues: Potential Implications as a Cancer Therapeutic Target [J].
Stepan, Lara P. ;
Trueblood, Esther S. ;
Hale, Kari ;
Babcook, John ;
Borges, Luis ;
Sutherland, Claire L. .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2011, 59 (07) :701-710
[76]   Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling [J].
Stoyanova, Tanya ;
Goldstein, Andrew S. ;
Cai, Houjian ;
Drake, Justin M. ;
Huang, Jiaoti ;
Witte, Owen N. .
GENES & DEVELOPMENT, 2012, 26 (20) :2271-2285
[77]   RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models [J].
Strop, Pavel ;
Tran, Thomas-Toan ;
Dorywalska, Magdalena ;
Delaria, Kathy ;
Dushin, Russell ;
Wong, Oi Kwan ;
Ho, Wei-Hsien ;
Zhou, Dahui ;
Wu, Aidong ;
Kraynov, Eugenia ;
Aschenbrenner, Laura ;
Han, Bora ;
O'Donnell, Christopher J. ;
Pons, Jaume ;
Rajpal, Arvind ;
Shelton, Dave L. ;
Liu, Shu-Hui .
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (11) :2698-2708
[78]   TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway [J].
Tang, Genxiong ;
Tang, Qi ;
Jia, Lizhou ;
Chen, Yuan ;
Lin, Liangyuan ;
Kuai, Xingwang ;
Gong, Aixiu ;
Feng, Zhengqing .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 44 (06) :2161-2170
[79]   Upregulation of Trop-2 quantitatively stimulates human cancer growth [J].
Trerotola, M. ;
Cantanelli, P. ;
Guerra, E. ;
Tripaldi, R. ;
Aloisi, A. L. ;
Bonasera, V. ;
Lattanzio, R. ;
de Lange, R. ;
Weidle, U. H. ;
Piantelli, M. ;
Alberti, S. .
ONCOGENE, 2013, 32 (02) :222-233
[80]   Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors [J].
Tsurutani, Junji ;
Iwata, Hiroji ;
Krop, Ian ;
Janne, Pasi A. ;
Doi, Toshihiko ;
Takahashi, Shunji ;
Park, Haeseong ;
Redfern, Charles ;
Tamura, Kenji ;
Wise-Draper, Trisha M. ;
Saito, Kaku ;
Sugihara, Masahiro ;
Singh, Jasmeet ;
Jikoh, Takahiro ;
Gallant, Gilles ;
Li, Bob T. .
CANCER DISCOVERY, 2020, 10 (05) :688-701